Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03455972
Other study ID # myeloma-03
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date February 20, 2018
Est. completion date December 2023

Study information

Verified date December 2020
Source The First Affiliated Hospital of Soochow University
Contact chengcheng fu
Phone 0086-0512-67781856
Email fuzhengzheng@suda.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CART therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see if this helps people with high risk multiple myeloma after auto-HSCT.To test the safety and efficacy of giving targeting CD19 and BCMA T cells in treating high risk multiple myeloma followed with auto-HSCT.


Description:

Adults ages 18-75 with high risk Multiple Myelomas (R-ISS III stage or with extramedullary infiltration or with del(17p), t(4;14), t(14;16), t(14;20), 1q21+ or disease progression during treatment). Design: Participants may be screened with: Medical history Physical exam Blood and urine tests Heart tests Bone marrow sample Multiple scans and X-rays Participants will have apheresis. Blood is removed through a needle in an arm. T cells are removed. The rest of the blood is returned through a needle in the other arm. The cells will be changed in a laboratory. Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the T cells through the IV within 3 days. Maintenance therapy with IMiDs was received after combined CAR T infusion. After this, participants will stay in the hospital for at least 9 days and stay nearby for 2 weeks. Then they will have blood tests and see a doctor. Participants will visit the clinic 1, 2, 3, 6, 9 and 12 months after the infusion, then every 3 months until disease progression. A bone marrow sample will be taken at the 3-month visit.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date December 2023
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Multiple myeloma patients eligible for auto-HSCT. - High risk multiple myeloma (R-ISS III stage or with extramedullary infiltration or with del(17p), t(4;14), t(14;16), t(14;20), 1q21+ or disease progression during treatment). - Expected survival = 3 months. - Creatinine < 2.0 mg/dl. - Blood coagulation function: PT and APTT <2x normal. - Arterial blood oxygen saturation>92%. - ALT(alanine aminotransferase)/AST (aspartate aminotransferase)< 3x normal - Karnofsky scores = 60 and ECOG score=2. - Adequate venous access for apheresis, and no other contraindications for leukapheresis. - Patients should not take immunotherapy in three months prior to CART cells infusion. - Voluntary informed consent is given. Exclusion Criteria: - Pregnant or lactating women. - Uncontrolled active infection. - Active hepatitis B or hepatitis C infection. - Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary. - Previously treatment with any gene therapy products. - Any uncontrolled active medical disorder that would preclude participation as outlined. - HIV infection. - History of myocardial infarction and severe arrhythmia in half a year. - Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease). - Patients with fever of unknown origin (T>38?).

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
anti-CD19 and anti-BCMA CAR
Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0) and anti-BCMA CAR T cells as split-dose (total 5×10e+7/kg, 40% on d1 and 60% on d2)
Drug:
Immunomodulatory drugs
Maintenance therapy

Locations

Country Name City State
China First Affiliated Hospital, Soochow University Suzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of Soochow University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of adverse events Proportion of subjects with adverse events overall and by severity grade Approximately 3 years
Primary PFS Is defined as time from first induction date to first documentation of PD, or death due to any cause, whichever occurs first. Minimum of 2 years after first induction
Primary OS Is defined as time from first induction date to time of death due to any cause Minimum of 2 years after first induction
Secondary Duration of best response According to IMWG response criteria at the end of the research. Minimum of 2 years
Secondary MRD negative conversion ratio and persistence MRD negative by flow cytometry Minimum of 2 years
Secondary Proportion of subjects who achieved Complete Response (CR) Rate Percentage of subjects who achieved CR or stringent CR according to IMWG Uniform Response Criteria for Multiple Myeloma Minimum of 2 years
Secondary Pharmacokinetics - Cmax Maximum transgene level Approximately 2.5 years after first CAR infused
Secondary Pharmacokinetics - Tmax Time to peak transgene level Approximately 2.5 years after first CAR infused
Secondary Pharmacokinetics - AUC Area under the curve of the transgene level Approximately 2.5 years after first CAR infused
Secondary Duration of persistence of CAR T cells in the blood Duration of persistence of CAR T cells in the blood Approximately 2.5 years after first CAR infused
See also
  Status Clinical Trial Phase
Recruiting NCT04994210 - Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL Phase 2
Terminated NCT05247957 - NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia N/A
Completed NCT04621123 - Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients Phase 2
Recruiting NCT05140616 - Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD Phase 1/Phase 2
Recruiting NCT05349552 - Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Completed NCT03820596 - Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL Phase 1/Phase 2
Completed NCT02018250 - Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS) Phase 1
Recruiting NCT04446806 - Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia Phase 4
Recruiting NCT05556889 - Safety and Analgesic Efficacy of a Modified Auriculotemporal Nerve Block N/A
Not yet recruiting NCT06244537 - Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer N/A
Completed NCT04785170 - Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals N/A
Recruiting NCT04677452 - Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM Phase 1
Completed NCT01305044 - The HEALS Project - Health Education and Active Living for Surviving Seniors Phase 2
Active, not recruiting NCT04646590 - A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 Phase 3
Recruiting NCT05021276 - Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD Phase 4
Not yet recruiting NCT05008666 - Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH Phase 2
Recruiting NCT06066840 - Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement Phase 4
Active, not recruiting NCT04852068 - A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells) Phase 3